logo
ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

439
Analysis
Health Care • China
WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.
more
bullish•Thematic (Sector/Industry)
•15 Sep 2022 01:04•Broker

The U.S. Executive Order on Its Biotech Industry May Not Materiality Affect Chinese CRO Industry

The U.S. launched new support to its biotech production, aiming to boost biomanufacturing in pharmaceuticals but also in other industries such as...

Logo
Quam Securities
212 Views
Share
bullish•Hang Seng Index
•10 Jun 2022 07:39•Syndicated

Hang Seng Index Constituents 8th June 2022

I got Alibaba spectacularly wrong. The government allowed the release of new games and eased some restrictions on the tech sector.

Logo
Share
bullish•Li Ning
•25 Oct 2021 00:00•Exchange-sponsored

New DLCs tracking CK Asset, China Merchants Bank, ANTA Sports, Li Ning & WuXi Biologics

Investors can now gain exposure to a wider range of Hong Kong stocks via SGX-listed DLCs with the listing of new DLCs tracking CK Asset, China...

Logo
Share

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.40.5

x